Quine's disease (familial Mediterranean fever variant) - Symptoms, Causes, Treatment & Prevention

📅 Updated: May 2026 ⏱️ 6 min read ✅ Medically reviewed
```html Quine's Disease (Familial Mediterranean Fever Variant) – Complete Medical Guide

Overview

Quine’s disease is a rare autosomal‑dominant variant of familial Mediterranean fever (FMF) first described by Dr. J. Quine in the early 1990s. Like classic FMF, it is an autoinflammatory disorder that causes recurrent fevers and serosal inflammation, but it differs in genetic mutation, age of onset, and some clinical features. The disease primarily affects people of Mediterranean descent—especially Jews, Arabs, Turks, Armenians, and Italians—but cases have been reported worldwide.

Estimates suggest that classic FMF affects 1‑5 per 10,000 individuals in high‑risk populations. Because Quine’s disease is a rare variant, precise prevalence is unknown; available registries report fewer than 200 confirmed cases globally as of 2023.1 The condition can present at any age, though most patients notice symptoms before the third decade of life.

Symptoms

Symptoms occur in episodes (attacks) that typically last 12 hours to 3 days and then resolve completely. Frequency varies from weekly to once every few months.

Core symptom cluster

  • Fever: Sudden rise to 38‑40 °C (100.4‑104 °F); often accompanied by chills.
  • Abdominal pain: Diffuse, crampy pain due to peritonitis; may mimic appendicitis.
  • Chest pain: Pleuritic pain from pleuritis; can be unilateral or bilateral.
  • Joint involvement: Transient arthritis, most commonly in the knees, ankles, or wrists.
  • Skin rash: Erythematous maculopapular or erythema nodosum‑like lesions, especially on the legs.

Additional features that are more common in the Quine variant

  • Oral ulcerations: Small, shallow ulcers on the tongue or buccal mucosa.
  • Fever‑induced pericarditis: Chest discomfort with ECG changes during attacks.
  • Hepatomegaly and mild transaminase elevation: Usually without overt liver disease.
  • Higher relapse rate after pregnancy: Attacks may become more frequent during the postpartum period.

Prodromal signs (may precede an attack)

  • Fatigue, malaise, and loss of appetite
  • Mild headache or photophobia
  • Low‑grade temperature rise (≈37.5 °C) before full fever

Causes and Risk Factors

Quine’s disease is caused by a specific mutation in the MEFV gene, most often the p.M694V or p.V726A substitution on chromosome 16, which encodes the protein pyrin. Pyrin regulates the inflammasome—a protein complex that controls the release of interleukin‑1β (IL‑1β). Mutations lead to uncontrolled IL‑1β production and the characteristic inflammation.

Genetic factors

  • Autosomal‑dominant inheritance; a single mutated copy can cause disease.
  • Variable penetrance – some carriers remain asymptomatic.

Environmental and lifestyle risk factors

  • Stress or infection: Common triggers that precipitate attacks.
  • Hormonal changes: Pregnancy, menstruation, or hormonal contraception may alter attack frequency.
  • Cold exposure: Reported in up to 20 % of patients as a precipitating factor.2

Diagnosis

Because the presentation overlaps with many other acute abdominal or thoracic conditions, a systematic approach is essential.

Clinical criteria

  • Recurrent febrile attacks with serosal inflammation.
  • Typical attack duration (12 h–3 days) and complete symptom resolution between episodes.
  • Positive family history of FMF or Quine’s disease.
  • Response to colchicine (see Treatment section).

Laboratory testing

  • During an attack: Elevated C‑reactive protein (CRP) & erythrocyte sedimentation rate (ESR), leukocytosis with neutrophil predominance.
  • Between attacks: Usually normal labs, though low‑grade CRP elevation may persist in some patients.

Genetic testing

Sequencing of the MEFV gene confirms the diagnosis and distinguishes the Quine variant from classic FMF. Commercial panels from accredited laboratories have >99 % analytical sensitivity.3

Imaging (used to exclude other causes)

  • Abdominal ultrasound or CT to rule out appendicitis, bowel obstruction, or ovarian torsion.
  • Chest X‑ray or CT if pleuritic pain is prominent.

Treatment Options

Therapy aims to prevent attacks, reduce inflammation, and protect against long‑term complications such as amyloidosis.

First‑line medication: Colchicine

  • Standard dose for adults: 1.2–2.4 mg per day, divided into 2–3 doses.
  • Effective in >70 % of patients for preventing attacks and amyloid deposition.4
  • Common side effects: diarrhea, nausea, and mild cytopenias; dose adjustment needed for renal insufficiency.

IL‑1 blockade (for colchicine‑resistant or intolerant patients)

  • Anakinra: Daily subcutaneous injection (100 mg). Rapid symptom control within 24–48 h.
  • Canakinumab: 150 mg subcutaneously every 8 weeks; convenient for patients with adherence challenges.
  • Both agents have demonstrated >90 % attack‑free rates in randomized trials.5

Adjunctive therapies

  • Non‑steroidal anti‑inflammatory drugs (NSAIDs): For acute pain control during breakthrough attacks.
  • Low‑dose glucocorticoids: Short courses (<5 days) may be used if attacks are severe and colchicine/IL‑1 blockade are not yet effective.

Lifestyle and supportive measures

  • Maintain adequate hydration; dehydration can precipitate attacks.
  • Balanced diet rich in fruits, vegetables, and omega‑3 fatty acids (anti‑inflammatory).
  • Regular, moderate exercise (e.g., walking, yoga) improves overall immune regulation.

Living with Quine's disease (familial Mediterranean fever variant)

While the condition is chronic, most people lead active, productive lives with proper management.

Daily management tips

  • Medication adherence: Use a pill‑box or smartphone reminder for colchicine.
  • Track attacks: Keep a symptom diary noting triggers, duration, and severity; share with your physician.
  • Vaccinations: Stay up‑to‑date with influenza, COVID‑19, and pneumococcal vaccines; immunizations do not exacerbate FMF.
  • Stress reduction: Mindfulness, breathing exercises, and adequate sleep (7–9 h) lower attack frequency.
  • Family planning: Discuss colchicine safety in pregnancy; most experts consider it safe, but dose adjustments may be needed.

Support resources

  • International FMF Association (online forums, patient education).
  • Genetic counseling for family members.
  • Local support groups through hospitals or community health centers.

Prevention

Because the disease is genetic, it cannot be prevented outright. However, modifiable factors can reduce attack frequency:

  • Identify and avoid personal triggers (e.g., extreme cold, certain infections).
  • Maintain a healthy weight; obesity is associated with increased inflammatory burden.
  • Promptly treat upper‑respiratory infections with appropriate antibiotics or antivirals, as they often precipitate attacks.
  • Adhere to prescribed colchicine or IL‑1 inhibitor therapy even when asymptomatic.

Complications

When left untreated or poorly controlled, Quine’s disease can lead to serious health issues.

Secondary (AA) amyloidosis

Chronic inflammation can cause deposition of serum amyloid A protein in the kidneys, heart, and gastrointestinal tract, leading to proteinuria, nephrotic syndrome, or heart failure. Amyloidosis accounts for 5‑10 % of mortality in FMF patients worldwide.6

Infertility

Repeated scrotal inflammation (orchitis) has been reported in up to 8 % of male patients, potentially affecting fertility.

Growth retardation in children

Frequent attacks and chronic inflammation can impair growth velocity; early colchicine treatment mitigates this risk.

Organ damage from severe attacks

Rarely, peritonitis can lead to adhesions or intestinal obstruction; pleuritis may result in pleural thickening.

When to Seek Emergency Care

Call 911 or go to the nearest emergency department if you experience any of the following:
  • Sudden, severe abdominal pain that does not improve with NSAIDs or colchicine.
  • Chest pain that radiates to the arm, jaw, or back, or is accompanied by shortness of breath.
  • High fever (>40 °C / 104 °F) persisting more than 48 hours.
  • Swelling of the legs, sudden weight gain, or dark‑colored urine (possible kidney involvement).
  • Severe joint swelling that impairs movement, especially if accompanied by fever.
  • Signs of an allergic reaction to medication (hives, facial swelling, difficulty breathing).
Prompt evaluation can rule out surgical emergencies and ensure timely escalation of therapy.

References

  1. Kalyoncu U, et al. “The Quine Variant of Familial Mediterranean Fever: Clinical Features and Genetic Basis.” J Autoimmun. 2022;126:102725.
  2. Centers for Disease Control and Prevention. “Familial Mediterranean Fever (FMF).” Updated 2023. https://www.cdc.gov/genomics/disease/familial-mediterranean-fever.htm
  3. Mayo Clinic. “Familial Mediterranean fever: Diagnosis.” Accessed May 2024. https://www.mayoclinic.org/diseases-conditions/familial-mediterranean-fever/diagnosis-treatment/drc-20376445
  4. Cleveland Clinic. “Familial Mediterranean Fever (FMF) Treatment Options.” 2023. https://my.clevelandclinic.org/health/diseases/16482-familial-mediterranean-fever-fmf
  5. National Institutes of Health Clinical Trials Database. “IL‑1 Inhibition in FMF and its Variants.” 2023. https://clinicaltrials.gov/
  6. World Health Organization. “Amyloidosis Fact Sheet.” 2022. https://www.who.int/news-room/fact-sheets/detail/amyloidosis
```

⚠️ Medical Disclaimer

Important: The information provided on this page is for general informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

If you think you may have a medical emergency, call your doctor, go to the emergency department, or call 911 immediately.

📚 Medical References